All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2023-04-19T09:22:28.000Z

Omidubicel-onlv granted FDA approval for patients with hematologic malignancies eligible for umbilical cord blood transplantation

Apr 19, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new development in the treatment of AML.

Bookmark this article

On April 17, 2023, omidubicel-onlv, a substantially modified allogeneic cord blood-based cell therapy, which has been discussed previously on the AML Hub here, here and here, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients aged ≥12 years with hematologic malignancies who are eligible for umbilical cord blood transplantation following myeloablative conditioning.1 Omidubicel-onlv contains stem cells derived from umbilical cord blood from an allogeneic pre-screened donor that are processed and cultured with nicotinamide before being administered as a single intravenous dose.1

This approval is based on results from a phase III randomized, multicenter study (NCT02730299) demonstrating efficacy and an acceptable safety profile of omidubicel-onlv compared with standard umbilical cord blood transplantation in 125 patients aged 12–65 years with acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes, or lymphoma.1 The trial notably included a high proportion of patients who were non-white (44%), a historically underrepresented population in registries of unrelated adult donors and umbilical cord blood.2

  • Neutrophil recovery was achieved by 87% of patients who received omidubicel-onlv versus 83% of patients who received standard umbilical cord blood transplantation.
    • Median time to neutrophil recovery was 12 days for patients who received omidubicel-onlv versus 22 days for those who received standard umbilical cord blood transplantation.
  • Patients who received omidubicel-onlv were found to have lower incidences of bacterial and fungal infections at 100 days post-transplantation (39%) compared with patients who received standard umbilical cord blood transplantation (60%).
  • The most commonly reported adverse events were infections, graft-versus-host disease, and infusion reactions.

As with all umbilical cord products, omidubicel-onlv has a Boxed Warning for infusion reactions, graft-versus-host disease, engraftment syndrome, and graft failure.1

  1. S. Food and Drug Administration. FDA approves cell therapy for patients with blood cancers to reduce risk of infection following stem cell transplantation. https://www.fda.gov/news-events/press-announcements/fda-approves-cell-therapy-patients-blood-cancers-reduce-risk-infection-following-stem-cell. Published Apr 17, 2022. Accessed Apr 18, 2022.
  2. ME Horwitz, PJ Stiff, C Cutler, et al. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase III randomized study. Blood. 2021 21;138(16):1429–1440. DOI: 1182/blood.2021011719

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
13 votes - 3 days left ...

Related articles

Newsletter

Subscribe to get the best content related to AML delivered to your inbox